JBJames Brauker

James Brauker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James Brauker has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Methods of Evaluating the Utility of Continuous Glucose Monitor Alerts

    by Apurv Kamath, Aarthi Mahalingam, James Brauker

    The evaluation of continuous glucose monitor (CGM) alert performance should reflect patient use in real time. By evaluating alerts as real-time events, their ability to both detect and predict low and high blood glucose (BG) events can be examined. True alerts (TA) were defined as a CGM alert occurring within ± 30 minutes from the beginning of a low or a high BG event. The TA time to detection was calculated as [time of CGM alert] - [beginning of event]. False alerts (FA) were defined as a BG event outside of the alert zone within ± 30 minutes from a CGM alert. Analysis was performed comparing DexCom™ SEVEN® PLUS CGM data to BG measured with a laboratory analyzer. Of 49 low glucose events (BG <70 mg/dl), with the CGM alert set to 90 mg/dl, the TA rate was 91.8%. For 50% of TAs, the CGM alert preceded the event by at least 21 minutes. The FA rate was 25.0%. Similar results were found for high alerts. Continuous glucose monitor alerts are capable of both detecting and predicting low and high BG events. The setting of alerts entails a trade-off between predictive ability and FA rate. Realistic analysis of this trade-off will guide patients in the effective utilization of CGM.


  • Continuous Glucose Sensing: Future Technology Developments

    by Jim Brauker

    The data from blood glucose meters are discontinuous, providing only an estimate of the “amount” of glucose. Continuous sensors provide time series data, including “amount,” but adding direction, rate of change, and rate of acceleration. Currently, continuous sensor labeling requires a fingerstick confirmation for treatment decisions and for periodic calibration. Because of the added information, sensors may be as efficacious and safe as meters when used for treatment decisions but have not yet been tested in stand-alone mode. Glucose sensors are currently in the early adopter's phase of technology development. To extend to the broader diabetes patient population, improvements are needed in reliability, comfort, ease of use, and integration with other technologies. In order to achieve a closed loop (artificial pancreas), the “Holy Grail” of the diabetes device industry, improvements in the accuracy of continuous sensors are also required. The main source of sensor inaccuracy is the calibration process. Calibration updates during the sensor wear period are required because of the gross changes in local metabolism (during the formation of the foreign body response) around the sensors after insertion and during the entire period of wear. Ambulatory sensors are currently approved and used only to treat insulin-using diabetes patients. In the future, the technology may have benefit for diagnostic use and behavior modification in obesity, metabolic syndrome, and prediabetes, as well as metabolic monitoring in elite athletes, soldiers, pilots, and the like. Hospitals currently use single-point information for tracking glucose in patients. Blood-based continuous sensing may provide the data needed to prevent in-hospital hypoglycemia and may lead to closed loop technology in the hospital.